United Therapeutics Corporation - Common Stock (UTHR)
308.59
-1.44 (-0.46%)
United Therapeutics is a biotechnology company focused on the development and commercialization of innovative therapies to treat chronic and life-threatening conditions, primarily in the fields of pulmonary hypertension and organ transplantation
Through its research efforts, the company aims to create and provide advanced medications that improve the quality of life for patients with severe health challenges. United Therapeutics is also engaged in initiatives to promote organ donation and transplantation, working towards enhancing the availability of organs for patients in need.
Shares of biotechnology company United Therapeutics (NASDAQUTHR)
fell 10.9% in the afternoon session after the company reported disappointing fourth-quarter results: EPS missed analysts' expectations, and sales were underwhelming, coming in line with expectations. We struggled to find many positives in these results, especially because EPS missed. Overall, this quarter could have been better.
Biotechnology company United Therapeutics (NASDAQUTHR) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 19.7% year on year to $735.9 million. Its GAAP profit of $6.19 per share was 1.2% below analysts’ consensus estimates.
United Therapeutics trades at $367.51 and has moved in lockstep with the market. Its shares have returned 13.5% over the last six months while the S&P 500 has gained 12.2%.
